Olema Pharmaceuticals Inc... (OLMA)
3.35
0.02 (0.60%)
At close: Apr 03, 2025, 3:59 PM
0.60% (1D)
| Bid | 3.32 |
| Market Cap | 228.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.2 |
| PE Ratio (ttm) | -1.52 |
| Forward PE | -2.28 |
| Analyst | Buy |
| Ask | 3.38 |
| Volume | 1,252,369 |
| Avg. Volume (20D) | 1,064,626 |
| Open | 3.24 |
| Previous Close | 3.33 |
| Day's Range | 3.15 - 3.43 |
| 52-Week Range | 3.15 - 16.62 |
| Beta | 2.12 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2020
Employees 96
Stock Exchange NASDAQ
Ticker Symbol OLMA
Website https://www.olema.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OLMA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 735.82% from the latest price.
Stock Forecasts4 months ago
+0.89%
Olema Pharmaceutical shares are trading higher aft...
Unlock content with
Pro Subscription
